Why not both? Biological doubles for RA and PsA

Why not both?  Biological doubles for RA and PsA

The introduction of tumor necrosis factor (TNF) inhibitors in the late 1990s revolutionized the treatment of rheumatic diseases, such as rheumatoid arthritis (RA) and psoriatic arthritis (PsA), providing patients with another therapeutic option when conventional therapies were ineffective. However, when these diseases fail to respond to anti-TNF therapy, it is still difficult to determine the … Read more